AdvaMed President Ubl Sets Ambitious FDA Performance, International Goals
This article was originally published in The Gray Sheet
Executive Summary
AdvaMed President Steve Ubl aims to have FDA meeting a 180-day review deadline for expedited PMAs in the next three to five years and to revamp Japan's reimbursement system in the next two years
You may also be interested in...
AdvaMed Hires Former Bush Aide As Top Lobbyist
A former aide to President Bush on health legislation will join AdvaMed Jan. 16 to head up the group's lobbying efforts
AdvaMed Hires Former Bush Aide As Top Lobbyist
A former aide to President Bush on health legislation will join AdvaMed Jan. 16 to head up the group's lobbying efforts
Industry Favors Predictability Over Speed In Next Round Of MDUFMA
Senior device industry staffers are more interested in improving the predictability of FDA's premarket review process than pushing the agency to accelerate its performance, an FDA 1report suggests